Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes
スポンサーリンク
概要
- 論文の詳細を見る
To investigate the long-term usefulness of immunosuppressive therapy (IST) for Japanese patients with lower-risk myelodysplastic syndromes, we retrospectively analyzed 29 MDS patients who were treated with cyclosporine A alone or with anti-thymocyte globulin at a single institute in Japan. A total of 58.6 % of patients showed hematological response to IST. Overall survival of all patients was 74.5 % at 5 years and 48.3 % at 10 years. The major adverse event was the elevation of creatinine level (grade 1 and 2). Eleven patients were still on IST at the time of analysis with, at least, some clinical benefits. Pneumonia was the most frequent cause of death (eight of 12 deaths), followed by bleeding (three of 12); most of the patients who died were non-responders. The presence of paroxysmal nocturnal hemoglobinuria-type cells was significantly associated with both response to IST and long-term survival by univariate analysis. The 10-year overall survival of responders (72.2 %) was significantly superior to that of non-responders (15.6 %, P < 0.0001). These results suggest that IST using cyclosporine A provides long-term benefit for Japanese patients with lower-risk MDS.
- 日本血液学会の論文
日本血液学会 | 論文
- 抗血小板tubulin抗体の血小板機能に及ぼす影響
- 血小板保存とMicrotubules
- Verapamilの血小板機能抑制の作用機序について
- 血小板機能の調節--プロスタグランディン系とcAMPの代謝の関連について〔英文〕 (第42回日本血液学会総会記録-2-) -- (血小板の機能と代謝(シンポジウム-2-))
- 好中球オプソニン抗体試験に関する基礎的並びに臨床的研究--異種血清および自己免疫性好中球減少症例における検討